A new guideline calls for physicians who screen asymptomatic men for prostate cancer to advise them about a multiyear regimen of medication that may reduce their risk of developing the disease. But the guideline also states that current evidence suggests the medication offers no benefit in reducing prostate cancer mortality or overall mortality. Nor does it dismiss the possibility that the drug might actually increase the risk of getting a higher-grade, and more deadly, form of this cancer.
Mitka M. Guideline Supports Long-term Use of Medication to Lower Prostate Cancer Risk. JAMA. 2009;301(17):1753-1754. doi:10.1001/jama.2009.560